Hyperion Lowers Price, Adds Shares in $50M IPO

Orphan disease firm Hyperion Therapeutics Inc. priced its initial public offering (IPO), shaving the price from the midpoint of $12 per share cited in its amended S-1 filing earlier this month to $10 per share – $1 below the proposed range – but upsizing the offering from 4.2 million to 5 million shares.